IMR Press / EJGO / Volume 18 / Issue 2 / pii/1997136

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Vulvar dystrophy: an evaluation of 285 cases

Show Less
1 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Hacettepe University School of Medicine, Ankara, Turkey
Eur. J. Gynaecol. Oncol. 1997, 18(2), 139–140;
Published: 10 April 1997

To determine the effectiveness of medical therapy in vulvar dystrophy, a retrospective, single-institute clinicopathologic study of 285 consecutive cases was carried out. Of the patients, 152 (53.3%) had squamous hyperplasia (SH), 72 (25.3%) had lichen sclerosus (LS), and 61 (21.4%) had lichen sclerosus with areas of squamous hyperplasia (LS+SH). Symptomatic response was 84.8% at 3 months and 92.7% at 6 months in patients with SH. These figures were 70.8% and 87.5% for patients with LS and 68.8% and 80.3% for patients with SH+LS, respectively. Histopathological response was 63.6% at 3 months and 74.8% at 6 months for patients with SH. These figures were approximately 29% and 42% for LS, and 21 % and 34% for patients with SH+LS, respectively. Corti­costeroids for squamous hyperplasia and testosterone for lichen sclerosus achieved a high symptomatic response. However, histo­logic remission rates were poorer.

Vulvar dystrophy
Lichen sclerosus
Back to top